Featured in Parola Analytics, Julie Carlisle explores how new therapeutic modalities are reshaping drug discovery.
In this article, we explore:
Rethinking the "Undruggable"
Many disease relevant proteins were once considered beyond the reach of conventional drug discovery. Julie Carlisle explains how emerging therapeutic modalities are enabling scientists to target these previously inaccessible proteins, opening new possibilities for treating disease.
Innovation driving new opportunities
Technologies such as PROTACs, LYTACs and RIBOTACs are expanding the drug discovery toolkit and broadening the range of therapeutic targets. As these approaches mature, they are creating exciting opportunities for both innovation and investment.
Evolving patent strategies
As science advances, patent portfolios are becoming more sophisticated. Julie highlights the growing importance of layered IP strategies that protect not only compounds, but also platforms, mechanisms, biomarkers and therapeutic applications.
Read the full article in Parola Analytics.
.png)
.png)